Bearish Risk: SUNPHARMA Faces US Tariff Threat on Specialty Drugs

Jefferies has warned that Sun Pharma is highly exposed to potential new US tariffs on medicines, specifically its specialty and innovative products manufactured in countries like South Korea and the EU. These tariffs could be as high as 15%, impacting the company's significant US revenue stream.

This matters for Indian markets as the US is a critical export market for Indian pharmaceutical companies. While generics might be spared, the focus on specialty drugs could set a precedent or expand to other product categories, creating uncertainty for the entire sector and potentially eroding profit margins for companies with global manufacturing footprints.

SUNPHARMA is directly negatively impacted due to its high exposure to specialty products and manufacturing locations. Other Indian pharmaceutical companies with significant US specialty product sales or manufacturing outside the US could also face indirect negative sentiment. The broader Nifty Pharma index might see pressure if these tariff threats materialize or expand.

Traders should closely monitor official announcements from the US administration regarding these tariffs, specifically the scope and product categories covered. Any confirmation or expansion of these tariffs could lead to further downside for SUNPHARMA and other exposed pharma stocks. Watch for management commentary from Sun Pharma on mitigation strategies.

• •Sun Pharma is identified by Jefferies as the most exposed Indian company to potential US tariffs on medicines.
• •Tariffs could be up to 15% on specialty and innovative products manufactured in countries like South Korea and the EU.
• •Generics may be exempt from these tariffs.
• •The US administration is reportedly preparing these tariffs, with an announcement possibly today (as of the article's publication date).